Published in Biotech Business Week, November 7th, 2005
The AZD-103 compound is, according to the companies, a promising disease-modifying therapeutic candidate for the treatment of Alzheimer disease.
This class of therapeutics provides significant advantages over the current products on the market which only treat disease symptoms, according to the companies.
Strong preclinical data have confirmed AZD-103's excellent safety profile and potential as a disease-modifying therapeutic for the treatment of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.